10-Q: SmartKem Faces Going Concern Amidst Rising Costs, Cash Drain

SmartKem, Inc. reported significant losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, despite a new lease agreement and increased operating income.

Summary

• Reported a net loss of $2.4 million for the three months ended June 30, 2025, and $4.5 million for the six months ended June 30, 2025.
• Cash and cash equivalents stood at $1.2 million as of June 30, 2025, a sharp decline from $7.1 million at December 31, 2024.
• Net cash used in operating activities was $6.1 million for the six months ended June 30, 2025.
• Operating expenses increased by 54.1% to $4.7 million for the three months ended June 30, 2025, compared to $3.0 million in the prior year period.
• Research and development expenses surged by 109.5% to $2.4 million for the three months ended June 30, 2025, primarily due to an $800,000 increase in costs from the CPI Framework agreement extension.
• General and administrative expenses rose by 28.0% to $2.4 million for the three months ended June 30, 2025, driven by increased professional service fees, including $0.3 million in non-cash expenses.
• The company renewed its lease for research & development, engineering, testing, and corporate offices in Manchester, England, for a term expiring in 2028, with an option to end the lease in 2027 for a fee of £105,188.50 (exclusive of VAT).
• All remaining 856 shares of Series A-1 Preferred Stock automatically converted into 690,788 shares of common stock and pre-funded Class C Warrants to purchase 1,282,412 shares of common stock on May 7, 2025.
• The 2021 Equity Incentive Plan was amended to increase the number of common stock shares reserved for issuance from 843,692 to 1,643,692 and set the evergreen share amount to 4% of outstanding common stock.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, rapid depletion of cash, significant and increasing operating losses, and reliance on future capital raises. While there are some positive developments like IP and a lease renewal, they are overshadowed by the severe financial distress and operational risks.

Positives

• Revenue for the six months ended June 30, 2025, increased to $55,000 from $40,000 in the same period of 2024.
• Other operating income increased to $0.5 million for the six months ended June 30, 2025, from $0.4 million in the prior year, primarily from research grants and R&D tax credits.
• Reported a non-operating income of $3.0 million for the six months ended June 30, 2025, largely due to a $3.2 million gain on foreign currency related to intercompany loan revaluation.
• Maintains an extensive IP portfolio with 140 granted patents across 17 patent families, 14 pending patents, and 40 codified trade secrets.
• Successfully renewed its key research and development facility lease in Manchester, UK, securing operational continuity until at least April 2027.

Negatives

• Incurred continuing net losses, with $4.5 million for the six months ended June 30, 2025, and an accumulated deficit of $119.2 million.
• Cash and cash equivalents significantly decreased to $1.2 million as of June 30, 2025, from $7.1 million at December 31, 2024, indicating a rapid cash burn.
• Net cash used in operating activities was $6.1 million for the six months ended June 30, 2025.
• The company's cash balance is not expected to be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Costs at the CPI facility have increased significantly since March 31, 2025, due to short-term extensions of the framework agreement, with expectations for continued higher costs under any longer-term agreement.
• Potential for significant delays and additional costs (2-9 months) if prototyping operations need to be moved to an alternative facility.
• Risk of losing approximately 11 key employees located at CPI if operations are relocated, particularly if the new facility is remote.
• Issuing equity securities to raise additional funds would likely result in dilution for existing security holders.
• Incurring indebtedness would lead to increased debt service obligations and potentially restrictive operating and financial covenants.
• Entering into collaborations or strategic alliances may require giving up valuable rights.

Risks

• Failure to secure additional funding to properly execute the business plan and satisfy operational needs.
• Development of new technological innovations by competitors that could impact the market for the company's products.
• Dependence on key personnel, with a risk of losing employees if operations are relocated.
• Reliance on third-party manufacturers and fabrication facilities, including the Centre for Process Innovation (CPI).
• Challenges in protecting proprietary technology and operating without infringing the intellectual property rights of others.
• Compliance with regulatory requirements, including those related to environmental legislation and energy performance.
• Significant increases in operating costs at the CPI facility, with expectations for continued higher costs under future agreements.
• Potential for significant delays (2-9 months) and additional costs if prototyping operations need to be moved to an alternative facility.
• Dilution of existing security holders if additional funds are raised by issuing equity securities.
• Increased debt service obligations and restrictive operating and financial covenants if debt financing is pursued.
• Forced to give up valuable rights if collaborations, strategic alliances, or licensing arrangements are entered into.
• Inability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market LLC.
• Impact of new semiconductor technologies, such as MicroLED, on the market acceptance of the company's organic semiconductor technology.
• Performance of organic semiconductor technology, whether perceived or actual, relative to competing semiconductor materials.
• Exposure to risks related to international operations, including foreign currency fluctuations.
• Uncertainty regarding the impact of new tax legislation (One Big Beautiful Bill Act) on financial statements.
• Potential liabilities from legal disputes in the normal course of business.

Future Outlook

The company anticipates operating losses to continue for the foreseeable future due to research funding, technology development, and commercialization expenses. Its current cash and cash equivalents are not sufficient to fund operating expenses and capital expenditures for the next 12 months. Future viability is dependent on raising additional capital through equity offerings, debt financings, collaborations, strategic alliances, or marketing/licensing arrangements. The company is also evaluating the impact of new U.S. federal tax law and new accounting standards.

Management Comments

• "The Company expects that its cash and cash equivalents of $1.2 million as of June 30, 2025 will not be sufficient to fund its operating expenses and capital expenditures for the 12 months from the issuance of these financial statements."
• "In the event that the Company is unable to raise additional capital in the near term, it may have to curtail its operations or seek protection under applicable bankruptcy or insolvency laws."
• "The Company expects that any longer-term agreement with CPIIS will require the Company to bear additional costs and that such costs will continue to be significantly higher than under the most recent agreement."
• "There is substantial doubt that the Company will be able to pay its obligations as they fall due, and this substantial doubt is not alleviated by management plans."

Industry Context

The company operates in the display industry, developing proprietary advanced semiconductor materials (TRUFLEX polymers) for applications in MicroLED, LCD, AMOLED, advanced computer and AI chip packaging, sensors, and logic. It faces competition from new semiconductor technologies and the need to demonstrate commercial viability against existing silicon-based and other products. The increased costs for prototyping services at CPI reflect broader pressures on specialized facility operations.

Corporate Governance

Stakeholder Impact

• Shareholders: Face significant risk of dilution from potential future equity offerings and substantial risk of value loss due to the 'going concern' warning and continued operating losses.
• Employees: Risk of job insecurity or relocation if operations are curtailed or moved, particularly for the 11 employees at the CPI facility.
• Customers and Collaborators: May experience disruptions or delays in product development and prototyping services due to operational uncertainties and potential facility changes.
• Creditors: Face increased risk of non-payment given the company's dwindling cash reserves and explicit 'going concern' warning.
• Suppliers: May face delays or non-payment for services, especially those related to the CPI facility where costs have increased and agreements are short-term.

Next Steps

• Negotiate and finalize a proposed three-year license agreement with CPI Innovation Services Limited (CPIIS) for clean room facilities.
• Explore and assess alternative sites for prototyping services, including the most effective allocation of capabilities between UK and Taiwan sites.
• Schedule prototyping activities to minimize disruption, potentially using ITRI's prototyping line as an interim facility during any relocation.
• Obtain additional funds through equity offerings, debt financings, collaborations, strategic alliances, or marketing/licensing arrangements to address the going concern issue.
• Continue evaluating the provisions of the newly enacted 'One Big Beautiful Bill Act' to assess its potential impacts on consolidated financial statements.
• Assess the potential impacts of adopting ASU No. 2024-03 on consolidated financial statements and related disclosures.

Key Dates

Recommendation

The company explicitly states 'substantial doubt' about its ability to continue as a going concern, with cash reserves projected to last less than 12 months. It has a significant and increasing net loss, a high cash burn rate, and rising operating expenses. While there are ongoing R&D efforts and IP, the immediate financial distress and the need for substantial capital raises, which will likely cause significant dilution, present an extremely high risk profile. A seasoned investor would view this as a critical red flag, warranting an immediate exit from the position.

Keywords

SmartKem, semiconductor materials, TRUFLEX, organic thin film transistors, OTFT, MicroLED, LCD, AMOLED, AI chip packaging, sensors, logic, SEC filing, 10-Q, financial results, going concern, research and development, intellectual property, lease agreement, CPI facility, capital raise